期刊文献+

柳氮磺吡啶肠溶片耐酸力和溶出度检测方法的建立与研究 被引量:2

Establishment and research of detection methods for acid tolerance and dissolution rate in sulfasalazine enteric-coated tablet
下载PDF
导出
摘要 目的建立柳氮磺吡啶肠溶片耐酸力和溶出度检测方法。方法溶出度试验采用篮法,依次以0.1 mol/L HCl和p H 7.5磷酸盐缓冲液作为溶出介质,转速100 r/min。高效液相色谱法对耐酸力和溶出度进行检测,采用Intersil ODS-3 C18(250 mm×4.6 mm,5μm)色谱柱,以水-异丙醇-乙腈-冰醋酸(22:11:7:0.4)为流动相,柱温40℃,流速为1.0 ml/min,检测波长为254 nm。结果柳氮磺吡啶浓度在25-300μg/ml范围内线性良好(r=0.9999);平均回收率(n=9)为100.1%,RSD为0.4%,溶液在24 h内稳定,滤膜对主药没有吸附。结论该耐酸力和溶出度检测方法准确、重现性好、操作简单,能够有效控制产品的内在质量。 Objective To establish detection methods for acid tolerance and dissolution rate in sulfasalazine enteric-coated tablet.Methods Basket method was applied in detection of dissolution rate, with 0.1 mol/L HCl and pH 7.5 phosphate buffer solution as dissolution media, and revolving speed by 100 r/min. High performance liquid chromatography was used in detection of acid tolerance and dissolution rate. Intersil ODS-3 C18 (250 mm×4.6 mm, 5μm) was chromatographic column, and water-isopropanol-acetonitrile-glacial acetic acid (22∶11∶7∶0.4) was mobile phase, with column temperature as 40℃, flow velocity as 1.0 ml/ min, and detection wave length as 254 nm.Results Sulfasalazine had good linear in 25-300μg/ml (r=0.9999), with the average recovery rate (n=9) as 100.1% andRSD was 0.4%. The solution was stable within 24 h, and basic remedy was not absorbed by filter membrane.Conclusion This is an accurate detection method for acid tolerance and dissolution rate, with good reproducibility and simple operation. It can effectively control inherent quality of product.
作者 孙宁云 常靓
出处 《中国现代药物应用》 2015年第17期273-276,共4页 Chinese Journal of Modern Drug Application
关键词 柳氮磺吡啶 耐酸力 溶出 高效液相色谱法 Sulfasalazine Acid tolerance Dissolution High performance liquid chromatography
  • 相关文献

参考文献3

二级参考文献11

  • 1Gu G Z, Xia H M, Pang Z Q, et al. Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromategraphy/tandem mass spectrometry and its application to a pharmacokinetic study[J]. J Chromatogr B, 2011, 879: 449-456.
  • 2Kita T, Sakaeda T, Adachi S, et al. N-acetyltransferasa 2 genotype correlates with sulfasarazine pharmacokinetics after multiple dosing in healthy Japanese subjects[J]. Biol Pharm Bull, 2001,24(10): 1176-1180.
  • 3Ma J J, Liu C G, Li J H, et al. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population[J]. Clin Chim Acta 2009, 407:30-35.
  • 4CDER/FDA. Guidance for Industry, Bioavailability and Bio- equivalence Studies for Orally Administered Drug Products-Gen- eral Considerations, March 2003. http://www, fda. gov/down- loads/Drugs/Guidance Compliance Regulatory Information/ Guida /UCM070124. pdf.
  • 5FDA. Draft Guidance on Sulfasalazine,Feb 2010. http://www. fda. gov/downloads/Drugs/Guldance Compliance Regulatory In- formation/Guidances/UC M 199673. pdf.
  • 6Ma JJ,Liu CG,Li JH,et al. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population [ J ]. Clin Chem Acta,2009,407 : 30.
  • 7Gu GZ, Xia HM, Pang ZQ, et al. Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromategraphy/tandem mass spec- trometry and its application to a pharmacokinetic study [J].J Chromtog B ,2011,879:449.
  • 8杜凯阳,肖征宇.柳氮磺吡啶治疗类风湿关节炎研究进展[J].中国药物与临床,2008,8(6):480-482. 被引量:9
  • 9李金恒,刘存刚,姚旋,曹晓梅,倪立,马晶晶,贺阳红.HPLC梯度洗脱法测定血浆中柳氮磺吡啶及其代谢物[J].医学研究生学报,2008,21(7):682-684. 被引量:7
  • 10白小红,付永丽.分光光度法测定柳氮磺胺吡啶及其代谢物磺胺吡啶浓度的研究[J].山西医科大学学报,2003,34(3):278-280. 被引量:3

共引文献6

同被引文献8

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部